$18,002.96 consulting Payment -- Roche/Genentech to Dr. Amanda Lewis

Hematologist Receives $18K Consulting Fee from Roche/Genentech for Ocrevus

This page provides a detailed analysis of a $18,002.96 consulting payment from Roche/Genentech to Dr. Amanda Lewis. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$18,002.96
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyRoche/Genentech
PhysicianDr. Amanda Lewis
NPI Number1840661649
Physician SpecialtyHematology
LocationCity, WI
Date of Payment2026-03-21
Related Drug/DeviceOcrevus
Conflict AssessmentHigh -- Significant

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Roche/Genentech made a $18.0K consulting payment to Amanda Lewis, a Hematology specialist in City, WI. The payment was associated with Ocrevus. The payment of $18,002.96 to Dr. Amanda Lewis from Roche/Genentech for consulting services is a significant amount. The payment is specifically tied to consulting related to Ocrevus, a drug used in Hematology. The payment date is in the future (March 21, 2026), which is unusual for reported payments.

Patient Guidance: What This Payment Means for You

This information relates to a payment made to your physician for consulting services. It is important to understand how such payments might influence medical advice. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees for specialists like Hematologists can vary widely, but $18,002.96 is on the higher end for a single reported payment, suggesting a substantial engagement.

Regulatory Context: Sunshine Act Requirements

Physicians must disclose payments from pharmaceutical companies as required by the Sunshine Act to ensure transparency in healthcare.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $18.0K payment for?

This was a consulting payment of $18.0K from Roche/Genentech to Amanda Lewis, categorized as "Consulting Fee". It was associated with Ocrevus. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Amanda Lewis accept pharmaceutical money?

Yes, Amanda Lewis received this $18.0K payment from Roche/Genentech. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Amanda Lewis's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $18.0K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Hematology?

To compare this payment against Hematology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hematology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Amanda Lewis's relationship with Roche/Genentech?

The payment is categorized as a 'Consulting Fee', indicating a service provided by the physician. This $18.0K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Hematology?

The amount is substantial, suggesting a significant consulting engagement.

What should patients do after learning about this payment?

This information relates to a payment made to your physician for consulting services. It is important to understand how such payments might influence medical advice.

What else should I know about this consulting payment?

The payment is linked to a specific drug, Ocrevus, highlighting a potential focus on that product.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.